Search

A 15-amino-acid fragment derived from a stomach-protecting protein, widely studied in rodents for gut, tendon, and ligament repair.

A synthetic fragment of thymosin beta-4 studied in animals for wound healing, cardiac repair, and tissue regeneration.

A naturally occurring copper-binding tripeptide widely used in cosmetics and studied for skin remodeling and wound healing.

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

An investigational triple GLP-1 / GIP / glucagon receptor agonist showing the largest weight-loss effects yet seen in mid-stage trials.

A 29-amino-acid GHRH analog formerly FDA-approved for childhood growth hormone deficiency.

A long-acting GHRH analog studied as a research peptide for sustained growth hormone elevation.

A selective ghrelin receptor agonist studied as a growth hormone secretagogue with minimal effects on cortisol or prolactin.

A melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

A central coenzyme in energy metabolism that has been studied as a supplement and IV therapy for aging, fatigue, and metabolic health.

A mitochondrial-encoded peptide studied for its role in metabolism, exercise capacity, and mitochondrial signaling.

A long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.

A 16-amino-acid C-terminal fragment of human growth hormone studied for fat metabolism, with disappointing weight-loss outcomes in humans.

A four-amino-acid peptide studied primarily in Russian and Eastern European research for longevity, sleep, and antioxidant effects.

A Russian-developed heptapeptide analog of tuftsin studied as a nasal anxiolytic with minimal sedation in small clinical trials.

A Russian-developed ACTH(4-10) analog used intranasally and studied for cognitive performance and stroke recovery.

A cyclic melanocortin receptor agonist that increases skin pigmentation; precursor research peptide that led to bremelanotide.

A 28-amino-acid immunomodulatory peptide approved in many countries (as Zadaxin) for hepatitis B and as an adjunct in cancer and infection.

An upstream regulator of the reproductive axis studied for fertility, hypothalamic amenorrhea, and sexual arousal pathways.

A human cathelicidin antimicrobial peptide central to skin and respiratory innate immunity.

Delta sleep-inducing peptide, a nonapeptide studied for slow-wave sleep and stress modulation since the 1970s.

The C-terminal tripeptide of α-MSH studied for anti-inflammatory effects in gut and skin disease.

A small-molecule NNMT inhibitor studied in obese mice for reducing fat mass and raising cellular NAD+ and SAM levels.

A linear analog of α-melanocyte-stimulating hormone (α-MSH) that activates the melanocortin-1 receptor to stimulate eumelanin production. As the drug afamelanotide (SCENESSE), it is FDA-approved for a rare light-sensitivity disorder; the grey-market 'tanning peptide' sold under this name is unapproved.

A nine-amino-acid neuropeptide and hormone best known for its role in childbirth and lactation; FDA-approved as an injectable drug (Pitocin) for labor, and heavily studied (often via nasal spray) for social bonding, trust, anxiety, and autism with mixed, frequently non-replicating results.

A mitochondria-targeting tetrapeptide (elamipretide) that binds cardiolipin on the inner mitochondrial membrane; it has been tested in multiple human trials and gained FDA accelerated approval for the ultra-rare Barth syndrome in 2025, though several other primary endpoints were not met.

Mechano Growth Factor (MGF) is a locally-acting splice variant of IGF-1 (IGF-1Ec) studied for its proposed role in activating muscle stem cells and triggering early muscle repair after mechanical loading. Evidence is almost entirely animal and cell-culture based, with no human therapeutic trials.

A popular research-peptide stack pairing the GHRH analog CJC-1295 (no-DAC / Mod GRF 1-29) with the selective secretagogue ipamorelin, intended to amplify natural growth-hormone release. No human trials exist on the combination itself.

A research stack combining tesamorelin (an FDA-approved GHRH analog for HIV-associated visceral fat) with ipamorelin, aimed at fat loss and growth-hormone support. No human trials exist on the combination itself.

A recovery-focused research blend pairing BPC-157 with TB-500, marketed for soft-tissue and injury repair. Both components have only animal-level evidence, and there are no human trials of the combination.

An extended recovery stack adding Mechano Growth Factor (MGF) to the BPC-157 + TB-500 blend, aiming to layer muscle-stem-cell activation onto tissue repair. All three components are animal/lab-level only, with no human or combination trials.

A skin-and-recovery research blend combining the copper peptide GHK-Cu with TB-500 and BPC-157, marketed for skin quality and tissue repair. GHK-Cu has human cosmetic data; the other two are animal-only, and the combination is untested.

An anti-inflammatory extension of the Glow blend that adds KPV (an α-MSH fragment) to GHK-Cu, TB-500, and BPC-157, aiming to combine skin remodeling, tissue repair, and inflammation control. The four-peptide combination is untested in humans.

A nootropic research blend pairing the anxiolytic peptide Selank with the cognitive/neuroprotective peptide Semax, both Russian-developed. Each has some human data (mostly Russian trials); the combination itself has not been formally studied.